David Borg

affiliated with the university
More filtering options
  1. 2019
  2. 2018
  3. 2017
  4. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial

    Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., De Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G. W., Cummins, S. & 14 othersRoss, P. J., Wasan, H., McDonald, A., Crosby, T., Ma, Y. T., Patel, K., Sherriff, D., Soomal, R., David Borg, Sothi, S., Hammel, P., Hackert, T., Jackson, R. & Büchler, M. W., 2017, In : The Lancet. 389, 10073, p. 1011-1024

    Research output: Contribution to journalArticle

  5. 2016
  6. Pancreatic cancer: Yesterday, today and tomorrow

    Daniel Ansari, Bobby Tingstedt, Bodil Andersson, Fredrik Holmquist, Sturesson, C., Caroline Williamsson, Sasor, A., David Borg, Bauden, M. & Roland Andersson, 2016 Aug 1, In : Future Oncology. 12, 16, p. 1929-1946 18 p.

    Research output: Contribution to journalArticle

  7. 2015
  8. 2009